Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lubiprostone in Chronic Idiopathic Constipation
NCT02651155Phase 3Completed
- Sponsor
- Takeda
- Start
- Mar 2016
- Primary completion
- Jan 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic idiopathic constipation (CIC) comparing Lubiprostone 24 μg with Placebo (2 arms). Primary endpoint: Spontaneous Bowel Movement Frequency at 1 week. Started Mar 2016; status: completed.
02
Drugs
lubiprostone
03
Conditions
chronic idiopathic constipation (CIC)
Beyond the preview
Go deeper on NCT02651155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02651155.